Skip to content

Evaluation of the control of risk factors to develop ATHEROsclerosis in patients treated by general practioners in Belgium and Luxembourg

Cross-sectional study evaluating the control of risk factors to develop ATHEROsclerosis in the general population of Belgium and Luxembourg treated with at least one antihypertensive agent and a statin.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN12117571
Enrollment
4725
Registered
2018-01-16
Start date
2018-02-01
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension Circulatory System Hypertension

Interventions

All participants attend an appointment to see their general practitioner, who is asked to record the following information: 1. Number of the patient in the study (1 to 15)

Sponsors

Servier Benelux
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age = 18 years 2. Confirmed (in medical records) diagnosis of hypertension 3. Confirmed (in medical records) diagnosis of hypercholesterolemia or stable coronary artery disease 4. Prescription of = 1 antihypertensive drug 5. Prescription of a statin

Exclusion criteria

Exclusion criteria: Patients hospitalised for cardiovascular diseases in the last 3 months (including revascularization).

Design outcomes

Primary

MeasureTime frame
1. Systolic and diastolic blood pressure values is measured using according to the general practitioners’ standard operating procedure during consultation 2. LDL-c and total cholesterol is noted based on medical records at time of consultation

Secondary

MeasureTime frame
1. Number of antihypertensive and cholesterol lowering drugs taken before consultation is measured using medical records 2. Cardiovascular risk of on-treatment patients in Belgium and Luxembourg is measured using medical records and patient anamnesis during consultation 3. Judged BP control and cholesterol control is measured by asking the general practitioners’ clinical evaluation during consultation 4. Judgement of the suitability of the patient for single pill combinations & motivation is measured using by asking the general practitioners’ clinical evaluation during consultation 5. Types of antihypertensive and lipid lowering treatment used in Belgium and Luxembourg is measured using medical records

Countries

Belgium, Luxembourg

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026